Is Novavax Stock a Buy?

Jason Hawthorne, The Motley Fool
·7 min read
Is Novavax Stock a Buy?

The initial readouts of phase 3 trials for COVID-19 vaccines have been impressive. All this progress, and ongoing plans to start administering these vaccines (when approved) to those most at risk, is wonderful news -- but where does it leave companies still working through clinical trials of their own candidates? Novavax (NASDAQ: NVAX) chose a potential vaccine to test in April, and has experienced both progress and setbacks since.